Atopic dermatitis and psychosocial comorbidities

Introduction

Typical comorbidities in patients with atopic dermatitis (AD) include allergic asthma, allergic rhinoconjunctivitis, and food allergy [1]. In addition, it has been shown that AD is associated with a number of other diseases, particularly autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease [2], systemic lupus erythematosus [3], vitiligo [4], and alopecia areata [5–7]. As early as 1942, atopic individuals were described as being tense, nervous, depressed, introverted and anxious [8]. The goal of the present article is to provide an overview of psychosocial comorbidities currently known to be associated with AD.

Methods

Using the terms atopic dermatitis/eczema, comorbidity, depression, anxiety, attention-deficit/hyperactivity disorder, anorexia, obsessive compulsive disorder, quality of life, sleep, schizophrenia, we conducted a literature search in PubMed. Articles published over the course of the past 10 years were included in our analysis. We identified 21 studies, including cross-sectional studies, case-control studies, and randomized placebo-controlled trials. The number of patients included in the various studies ranged from 30 to 120,508. The diagnostic definitions we used in our discussion of the various psychosocial disorders are based on current guidelines [1, 9–15].

Depression, anxiety disorders and suicidal tendencies (Table 1)

The diagnosis of depression is made when two of the following three main symptoms are present: depressed/subdued mood, loss of interest or pleasure, psychomotor retardation, increased fatigue/low energy. Other possible symptoms include the following: decreased ability to concentrate, low self-esteem/confidence, feelings of guilt/worthlessness, negative/pessimistic views of the future, suicidal ideation, self-injury or suicide attempts, sleep disorders and decrease in appetite [9].

As regards anxiety disorders, a distinction is made between panic disorder, generalized anxiety disorder, social...
phobia, and specific phobias [10]. Both depression and anxiety disorders may lead to suicide [11].

In the US, a cross-sectional study revealed that patients with AD significantly more frequently showed symptoms of depression such as loss of interest, hopelessness, decrease in appetite, fatigue, and decreased ability to concentrate [16]. This association is most likely bidirectional: on the one hand, AD increases a patient’s risk of depression [17]; on the other hand, stress is a known trigger of AD [18].

A German cross-sectional study showed an increased risk of suicidal ideation and found symptoms of depression, high disease activity, young age and a weak family bond to be significant predictive factors in this context [19]. According to a Korean cross-sectional study, there is a significantly increased risk of having anxiety disorders and depression, irrespective of their own atopic status [23]. In their 2018 meta-analysis, Rønnstad et al. demonstrated a significant association of AD with depression and anxiety. However, their analysis was limited in that the various studies had used different definitions of depression and anxiety. Moreover, only few studies had included an assessment of disease severity and of its impact on psychosocial disorders [24].

Depression seems to be associated with the presence of proinflammatory cytokines, in particular tumor necrosis factor (TNF)-α, interleukin 6 and CRP [25].

In a randomized, placebo-controlled trial, treatment with the interleukin 4 receptor antagonist dupilumab resulted in improvement in quality of life (DLQI) as well as a decrease in depressive symptoms and anxiety (HADS). Interleukin 4 and interleukin 13 are key cytokines in Th2-mediated inflammation in patients with AD [26]. In summary, the evidence currently available strongly suggests an association of AD with depression, anxiety disorders, and suicidal tendencies. However, more research is needed to corroborate this association and to evaluate the impact disease severity and treatment may potentially have.

Attention-deficit/hyperactivity disorder (ADHD) (Table 2)

ADHD is characterized by the three symptoms inattention, impulsivity, and hyperactivity [12].

In a case-control study, Tsai et al. showed that children with AD and other atopic diseases (allergic asthma, allergic rhinitis or allergic conjunctivitis) were at a greater risk of developing ADHD. In addition, the risk increased with the number of atopic diseases an individual had; the risk was also greater in individuals living in urban areas [27]. In another case-control study, Schmitt et al. also saw a significant association between ADHD and AD, irrespective of age, gender and other psychiatric disorders. The likelihood of developing ADHD increased with each AD-related doctor’s visit [28, 29]. A prospective, non-interventional study has suggested that the risk of developing ADHD increases with the use of antihistamines in early childhood [30]. Moreover, it has been shown that children with AD significantly more often exhibit oppositional defiant behavior and autism spectrum disorders [31]; the longer AD persists, the greater is the association with mental health problems [32].

Schizophrenia (Table 3)

Schizophrenia is a syndrome characterized by various mental impairments, including perception, cognition, ego functions, affectivity, lack of energy, and psychomotor activity [13].

There is only little – and partly controversial – data on the association of schizophrenia and AD. In one study, it was shown that the presence of AD, urticaria, or allergic rhinitis in the absence of asthma significantly increased the risk of schizophrenia [33]. For schizophrenia too, an association with proinflammatory cytokines and Th17 cells has been suggested [34]. Besides, a significant increase in the prevalence of ischemic stroke has been reported in patients with schizophrenia and atopic diseases [35]. In another study, however, seropositivity for specific IgE antibodies was significantly lower in patients with schizophrenia, suggesting a lower prevalence of atopic diseases in schizophrenic individuals [36].

Obsessive-compulsive disorder (Table 4)

Obsessive-compulsive disorder is characterized by recurrent, stereotypic thoughts and behaviors. There are four subgroups: 1) compulsive checking; 2) compulsive repeating and ordering/arranging; 3) compulsive washing and cleaning; 4) hoarding disorder [37, 38].

There are hardly any studies on the correlation of AD and obsessive-compulsive disorder. One study examined the association of obsessive-compulsive symptoms in mothers of children with AD. The disease had no impact on the
### Table 1 Data on depression, anxiety disorders and suicidal tendencies in patients with AD.

| Author/year | Study design | Parameters                                                                 | Number of patients | Country | Conclusion |
|-------------|--------------|----------------------------------------------------------------------------|---------------------|---------|------------|
| Yu et al. [16] 2015 | Cross-sectional study NHANES 2005–2006 | PHQ-9 (patient health questionnaire) SIGECAPS (symptoms related to sleep, interest, guilt, energy, concentration, appetite, psychomotor activity, suicidal tendencies) | 5,555 (≥ 18 years) | USA | – Increased prevalence of depression in patients with AD (17.5 vs. 10.5%; OR 1.89)  
– Higher risk of moderate (OR 2.24) and severe (OR 5.64) depressive episodes |
| Kim et al. [17] 2015 | Cross-sectional study Survey among military draftees 2008 to 2012 | Survey on depression, anxiety, and somatization based on medical files, history, and psychological tests | 120,508; 1,517 (1.2%) thereof had AD (19–21 years) | South Korea | – Psychological stress significantly more common in draftees with AD  
– Risk of depression (OR 1.79), anxiety (OR 1.38), and somatization (OR 1.75) significantly higher in AD  
– Moderate/severe AD significantly more often associated with depression and somatization than mild AD |
| Dieris-Hirche et al. [19] 2017 | Cross-sectional study | Questionnaires: Pöldinger’s scale for suicide risk assessment, HADS, DLQI, PO-SCORAD, Skin Satisfaction Questionnaire (SSQ). | 181 with AD, 64 control subjects (18–65 years) | Germany | – High prevalence of suicidal ideation in patients with AD (21.3%)  
– 3.9% of patients with acute suicidal tendencies  
– Predictive factors for suicidal tendencies: depressive symptoms, severe AD, young age, little family support |
| Lee et al. [20] 2017 | Cross-sectional study | Questionnaires on depression, anxiety, suicide and AD | 72,435 students of junior high schools and high schools (12–17 years) | Korea | – Compared to control subjects, adolescents with AD had a higher risk of depressive symptoms (OR 1.27), suicidal ideation (OR 1.34), plans to commit suicide (OR 1.46) and suicide attempts (OR 1.51) |
| Author/year | Study design | Parameters | Number of patients | Country | Conclusion |
|------------|-------------|------------|--------------------|---------|------------|
| Thyssen et al. [21] 2017 | Cross-sectional study | Danish study of functional disorders (DanFusnD) | – Questionnaire on depression, anxiety, symptoms of AD, consumer behavior, suicidal tendencies – Criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) – Rate of hospitalization due to depression or anxiety disorders – Suicides in the National Causes of Death Registry – Prescription of anxiolytic agents and antidepressants in the Registry of Medicinal Product Statistics | 9,656; 1,044 (13.8 %) thereof had AD (≥ 18 years) | Denmark | – Significant association between AD and depression (OR 1.92) and anxiety disorders (OR 1.74) – Patients with AD significantly more often had depressive symptoms (OR 2.15) – Suicidal ideation more common in AD patients (3.4 % vs. 1.7 %) – Rate of hospitalization not increased compared to general population – Risk of suicide very low in both AD patients and control subjects (n = 4 vs. n = 5) – Patients with moderate-to-severe AD were significantly more often taking anxiolytic agents (OR 1.66) and antidepressants (OR 1.24) – Patients with mild AD showed only a slight increase in the use of anxiolytic agents (OR 1.08) |
| Mina et al. [22] 2015 | Cross-sectional study | – Primary Care Evaluation of Mental Disorders (PRIME-MD) | 81 (36 men, 45 women) (10–74 years) | India | – 15 % had moderate/severe depression; 12 % had anxiety disorders – Women: significantly higher scores for depression and anxiety |
| Brew et al. [23] 2018 | Cross-sectional study | – Screen for Child Anxiety-related Emotional Disorders (SCARED) – Shortened Mood and Feelings (SMFQ) | 14,197 children (9 years) | Sweden | – If a twin had at least one atopic disease, the other twin had an increased risk of developing an anxiety disorder or depression, irrespective of the latter’s own atopic status (OR 1.22) |
| Simpson et al. [26] 2016 | Randomized, placebo-controlled phase 3 SOLO 1, SOLO 2 | – DLQI, HADS | 671 in SOLO 1, 708 in SOLO 2 (25–51 years) | USA Europe Asia | – After 16 weeks of dupilumab therapy, significant improvement in DLQI (by ≥ 4 points) compared to baseline – After 16 weeks of dupilumab therapy, significantly higher reduction in HADS (down to < 8 points) compared to baseline |

Abbr.: HADS, Hospital Anxiety and Depression Scale, DLQI, Dermatology Life Quality Index, PO-SCORAD, Patient-oriented Scoring Atopic Dermatitis; OR, odds ratio.
Table 2 Data on attention-deficit/hyperactivity disorder (ADHD) in patients with AD.

| Author/year | Study design            | Parameters                                      | Number of patients                        | Country          | Conclusion                                                                                     |
|-------------|-------------------------|-------------------------------------------------|--------------------------------------------|------------------|----------------------------------------------------------------------------------------------|
| Tsai et al. [27] 2013 | Case-control study Longitudinal Health Insurance Database | Medical diagnosis (DSM-5/ICD-9)                 | 4,692 children with ADHD and 18,768 control subjects (< 18 years) | Taiwan          | Increased risk of developing ADHD in patients with AD (OR 1.80), asthma (OR 1.48), allergic rhinitis (OR 1.81) or allergic conjunctivitis (OR 1.69) | Risk increases with number of atopic diseases |
| Schmitt et al. [29] 2013 | Case-control study Secondary data from AOK Plus (statutory health insurance fund) and KV (association of physicians in the statutory health insurance sector) in Saxony, 2003–2004 | Medical diagnosis (ICD-9)                     | 1,436 children with AD and 1,436 control subjects (6–17 years) | Germany         | Significant association between AD and ADHD (OR 1.54, p = 0.02) | Likelihood of developing ADHD increased with each AD-related doctor’s visit (OR 1.06; p = 0.046) | Association independent of age, gender, and other psychiatric disorders (OR 1.47, p = 0.046) | Atopic comorbidities not significantly associated with ADHD (asthma OR 1.72, p = 0.07; allergic rhinitis OR 1.46; p = 0.055) |
| Schmitt et al. [30] 2017 | Prospective, non-interventional | Medical diagnosis (ICD-10), SCORAD, POEM (patient-oriented eczema measure), history, questionnaire | 154 children 42 with AD, 34 with ADHD, 31 with AD and ADHD, and 47 control subjects (6–12 years) | Germany         | Compared to the control group, children with AD only, ADHD only, or AD and ADHD had a significantly increased risk of behavioral problems and lower quality of life | Higher risk of ADHD symptoms in children with AD than in control subjects | Antihistamine use by children with AD was significantly associated with a higher incidence of ADHD symptoms (OR 1.88; 95 % CI 1.04–3.39). | Current severity of AD symptoms had no impact on the severity of ADHD symptoms |
| Yaghmaie et al. [31] 2013 | Cross-sectional study 2007 National Survey of Children’s Health | Questionnaire on the severity of AD and the presence of a mental disorder (depression, anxiety disorder, behavioral disorder, autism) | 92,642 children (0–17 years) | USA             | Risk of ADHD significantly increased in children with AD (OR 1.87); increased risk of depression (OR 1.81), anxiety disorder (OR 1.77), behavioral disorder (OR 1.87), and autism (OR 3.04) | Correlation between severity of AD and prevalence of mental disorders |
| Schmitt et al. [32] 2010 | Birth cohort GINIplus | Questionnaire; assessment of AD symptoms, comorbidities, environmental factors | 2,916 children (1–10 years) | Germany         | Significantly higher risk of mental problems (OR 1.49) and emotional symptoms (OR 1.62) | Strength of association between AD and mental problems increased with the duration of AD |

*Abbr.*: OR, odds ratio.
severity of the mothers’ mental disorder and health-related quality [39].

**Anorexia nervosa**

Self-induced weight loss in combination with body dysmorphic disorder is the hallmark of anorexia nervosa [14]. For the time period analyzed, no data was found on anorexia nervosa in patients with AD.

**Sleep disorders (Table 4)**

Cardinal symptoms include difficulties falling and/or staying asleep and daytime drowsiness. As a consequence, patients experience fatigue that may cause impairment of both motor and mental functions as well as psychosocial performance (for example, dealing with stress) [15]. Sleep disturbances are problematic as they severely impair the quality of life of patients with AD [40, 41].

Several studies have shown sleep disturbances to occur not only in affected patients but also in the parents of children with AD. In particular, shorter sleep duration, difficulties falling asleep, early morning waking, and low sleep efficiency have been reported [40–42]. Poor sleep quality may result in impaired linear growth of atopic children [43].

**Quality of life (Table 5)**

Quality of life is defined as an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns [44]. The Dermatology Life Quality Index (DLQI) is one of the most widely used questionnaires on health-related quality of life (HRQoL), specifically developed for patients with skin diseases [45]. The Dermatitis Family Impact (DFI) questionnaire is a disease-specific tool to assess the impact of AD on the quality of life of the parents and family members of affected children [46].

Patients with AD have been shown to have a significantly lower quality of life and a higher level of stress than healthy

### Table 3 Data on schizophrenia in patients with AD.

| Author/ year | Study design | Parameters | Number of patients | Country | Conclusion |
|--------------|--------------|------------|--------------------|---------|------------|
| Pedersen et al. [33] 2012 | Cross-sectional study | Medical diagnosis (ICD-8) | 808,559; 3,539 thereof | Denmark | – Asthma significantly increased the risk of schizophrenia (OR 1.59)  
– Combination of any atopic disease increased the risk of schizophrenia (OR 1.35)  
– Presence of AD, urticaria, or allergic rhinitis in the absence of asthma significantly increased the risk of schizophrenia (OR 1.27) |
| Chen et al. [35] 2015 | Case-control study | Medical diagnosis (ICD-9) | 63,913 with schizophrenia (mean age 37.29 ± 14.32 years)  
63,913 control subjects (mean age 36.51 ± 14.13 years) | Taiwan | – Patients with schizophrenia are at increased risk of ischemic stroke  
– Risk of ischemic stroke increases with number of atopic comorbidities |
| Okusaga et al. [36] 2014 | Case-control study | Phadiatop multi-allergen | 66 with schizophrenia (mean age 42.2 ± 12.8 years)  
34 control subjects (mean age 41.5 ± 14.1 years) | Germany USA | – Prevalence of Phadiatop seropositivity was significantly lower in schizophrenic patients  
– Lower prevalence of atopy in schizophrenic patients (OR 0.40) |

*Abbr.: OR, odds ratio.*
Table 4  Data on obsessive-compulsive and sleep disorders in patients with AD.

| Author/year        | Study design                      | Parameters                                                                 | Number of patients                        | Country | Conclusion                                                                 |
|--------------------|-----------------------------------|-----------------------------------------------------------------------------|-------------------------------------------|---------|-----------------------------------------------------------------------------|
| Gunduz et al. [39] | Cross-sectional study             | SCORAD, Maudsley Obsessive Compulsive Inventory (MOCI), SF-36               | 120 children (mean age 1.5 ± 0.6) and their Mothers | Spain   | AD of children had no impact on the severity of the obsessive-compulsive disorder of their mothers in terms of obsessive-compulsive symptoms and HRQoL |
| Yu et al. [40]     | Cross-sectional study             | Questionnaire on AD and sleep disturbances                                  | 5,563 (≥ 18 years)                        | USA     | AD patients more frequently reported sleep disturbances (OR 1.62); shorter sleep duration (OR 1.61); difficulties falling asleep (OR 1.57); early morning waking (OR 1.86) |
| Chamlin et al. [41]| Cross-sectional study             | Questionnaire on sleep quality among parents of children with AD           | Parents of 300 children (0–6 years) with AD | USA     | More than 60 % of parents stated that AD affected their sleep or their children’s sleep  |
| Chang et al. [42]  | Case-control study                | Polysomnography, Actigraphy, 6-sulfatoxymelatonin urine levels, Total IgE levels | 72 patients, 32 control subjects (1–18 years) | Taiwan  | Lower sleep efficiency; difficulties falling asleep; increased sleep fragmentation; decrease in non-rapid eye movement sleep  |

Abbr.: SF-36, Short-Form Health Questionnaire; OR, odds ratio.

individuals. Quality of life decreases with increasing severity of AD [47]. The presence of a filaggrin mutation has been associated with impaired HRQoL [48]. Adequate treatment of AD has been shown to improve quality of life [49, 50].

Conclusions

Patients with AD may have a number of psychosocial comorbidities that need to be observed in their clinical care.
**Table 5** Data on quality of life in patients with AD.

| Author/year       | Study design     | Parameters                                                                 | Number of patients | Country   | Conclusion                                                                 |
|-------------------|------------------|----------------------------------------------------------------------------|--------------------|-----------|----------------------------------------------------------------------------|
| Kwak et al. [47]  | Cross-sectional  | EuroQol Visual Analogue Scale                                                | 11,913 (≥19 years) | Korea     | – HRQoL was significantly lower                                            |
|                   | study            |                                                                             |                    |           | – Increased risk of stress (OR 1.74), depression (OR 1.69) and suicidal ideation (OR 1.66) |
| Heede et al. [48] | Cross-sectional  | Questionnaire on skin symptoms, DLQI, mental/atopic diseases, Testing for filaggrin mutations | 520 (≥18 years)    | Denmark   | – Filaggrin mutations were detected in 16.9% of patients; significant association with reduced HRQoL but not with anxiety disorders or depression |
|                   | study            |                                                                             |                    |           | – 19.7% of patients with AD and filaggrin mutations reported severe or very severe impact on their lives; prevalence twice as high as in AD patients without filaggrin mutations (9.6%) |
| Coutanceau et al. | Cross-sectional  | SCORAD, PO-SCORAD, Patient-oriented Eczema Measure (POEM), Self-administered Eczema Area and Severity Index (SA-EASI), DLQI, Dermatitis Family Impact (DFI) questionnaire | 4,222 (0.1–97 years) | Europe    | – PO-SCORAD, SCORAD, POEM correlated with DLQI (r = 0.67) and DFI (r = 0.56) |
|                   | study            |                                                                             |                    |           | – After 5 weeks of treatment, there was a significant decrease in SCORAD and PO-SCORAD by 60% and 56%, respectively (p < 0.0001); improvement in quality of life |

**Abbr.:** DLQI, Dermatology Quality of Life Index; HRQoL, Health-related Quality of Life; OR, odds ratio.

Based on current data, there is an unequivocal association with depression, anxiety disorders and ADHD. However, the data currently available is by no means conclusive and further research is required to corroborate the association of AD with psychosocial comorbidities. For patients with moderate-to-severe disease in particular, it is recommended to assess the DLQI on a regular basis and, if necessary, to employ specific questionnaires on depression (for example, HADS). Other medical specialties should be involved in the management of these comorbidities as early as possible. More research is needed, especially with respect to the question as to how novel treatment options for AD may affect not only the cutaneous inflammation but also psychosocial comorbidities.

---

**Correspondence to**

Paula Kage, MD
Department of Dermatology, Venereology and Allergology
Leipzig Interdisciplinary Center for Allergology – LICA-CAC
University of Leipzig
Philipp-Rosenthal-Straße 23
04103 Leipzig, Germany
E-mail: paula.kage@uniklinik-leipzig.de

**References**

1. AWMF Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis] Entwicklungsstufe: S2k. AWMF online
Review Article

2015. Available from https://www.awmf.org/uploads/tx_szleitlinien/013-027l_S3k_Neuromotorik_2015-12-verlaengert.pdf [Last accessed September 9, 2019].

2 Schmitt J, Schwarz K, Baurecht H et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. Genetic analysis. J Allergy Clin Immunol 2016; 137(1): 130–6.

3 Wu LC, Hwang CY, Chung PI et al. Autoimmune disease comorbidities in patients with atopic dermatitis: a nationwide case-control study in Taiwan. Pediatr Allergy Immunol 2014; 25(6): 586–92.

4 Chen YT, Chen YJ, Hwang CY et al. Comorbidity profiles in association with vitiligo: A nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol 2015; 29(7): 1362–9.

5 Mohan GC, Silverberg JJ. Association of vitiligo and alopecia areata with atopic dermatitis: A systematic review and meta-analysis. JAMA Dermatol 2015; 151(5): 522–8.

6 Magen E, Chikovani T, Waitman DA, Kahan NR. Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria. Allergy Asthma Proc 2018; 39(2): 96–102.

7 Brunner PM, Silverberg JJ, Guttmann-Yassky E et al. Increasing comorbidity suggests that atopic dermatitis is a systemic disorder. J Invest Dermatol 2017; 137: 18–25.

8 Allerhand ME, Gough HG, Grais ML. Personality factors in neurodermatitis; a preliminary study. Psychosom Med 1950; 12: 386–90.

9 AWMF S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression – Kurzfaszung. AWMF online. 2017. Available from https://www.awmf.org/uploads/tx_szleitlinien/nv1-005l_S2k_Unipolare_Depression_2017-05.pdf [Last accessed September 9, 2019].

10 AWMF S3-Leitlinie Behandlung von Angststörungen. AWMF online. 2014. Available from https://www.awmf.org/uploads/tx_szleitlinien/051-028l_S3_Angstst%C3%B6rungen_2014-05-04.pdf [Last accessed September 9, 2019].

11 AWMF S2k-Leitlinie 028-031: Suizidalität im Kindes- und Jugendalter. AWMF online. 2016. Available from https://www.awmf.org/uploads/tx_szleitlinien/028-031l_S2k_Suizidalitaet _KJu_2016-07_01.pdf [Last accessed September 9, 2019].

12 AWMF S3-Leitlinie: Aufmerksamkeitsdefizit-/Hyperlaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. AWMF online. 2017. Available from https://www.awmf.org/uploads/tx_szleitlinien/028-045l_S3_ADHS_2018-06.pdf [Last accessed September 9, 2019].

13 AWMF S3-Leitlinie Behandlungsleitlinie Schizophrenie. AWMF online. 2019. Available from https://www.awmf.org/uploads/tx_szleitlinien/038-009l_S3_Schizophrenie_2019-03.pdf [Last accessed September 9, 2019].

14 AWMF S3-Leitlinie Diagnostik und Therapie der Essstörungen. AWMF online. 2011. Available from https://www.awmf.org/uploads/tx_szleitlinien/051-026l_S3_Essstoerung-Diagnostik-Therapie_2019-07_01.pdf [Last accessed September 9, 2019].

15 AWMF S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. AWMF online. 2017. Available from https://www.awmf.org/uploads/tx_szleitlinien/063-001l_S3_SBAS_2017-08_2.pdf [Last accessed September 9, 2019].

16 Yu SH, Silverberg JJ. Association between atopic dermatitis and depression in US adults. J Invest. Dermatol 2015; 135: 318–6.

17 Kim S-H, Hur J, Jang J-Y et al. Psychological distress in young adult males with atopic dermatitis: a cross-sectional study. Medicine (Baltimore) 2015; 94: e949.

18 LeBovidge JS, Elverson W, Timmons KG et al. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol 2016; 138: 325–34.

19 Dieris-Hirche J, Gieler U, Petrak F et al. Suicidal ideation in adult patients with atopic dermatitis: A German cross-sectional study. Acta Derm Venereol 2017; 97: 1189–95.

20 Lee S, Shin A. Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey. BMC Psychiatry 2017; 17(1): 3.

21 Thysen JP, Hamann CR, Linneberg A et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 2018; 73(3): 214–20.

22 Mina S, Jabeen M, Singh S, Verma R. Gender differences in depression and anxiety among atopic dermatitis patients. Indian J Dermatol 2015; 60: 211.

23 Brew BK, Lundholm C, Gong T et al. The familial aggregation of atopic diseases and depression or anxiety in children. Clin Exp Allergy 2018; 48: 703–11.

24 Rønstad ATM, Halling-Overgaard AS, Hamann CR et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol 2018; 79(3): 448–56.

25 Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24–31.

26 Simonson EL, Bieber T, Guttmann-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–48.

27 Tsai J-D, Chang S-N, Mou C-H et al. Association between atopic dermatitis and attention-deficit/hyperactivity disorder in childhood: a population-based case-control study. Ann Epidemiol 2013; 23: 185–8.

28 Schmitt J, Romansos M, Schmitt NM et al. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA 2009; 301: 724.

29 Schmitt J, Apfelbacher C, Heinrich J et al. Association of atopic eczema and attention-deficit/hyperactivity disorder – meta-analysis of epidemiologic studies. Z Kinder Jugendpsychiatr Psychother 2013; 41: 35–44.

30 Schmitt J, Buske-Kirschbaum A, Tesch F et al. Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. Allergy 2018; 73(3): 615–26.

31 Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131: 428–33.

32 Schmitt J, Apfelbacher C, Chen C-M et al. Infant-onset eczema in relation to mental health problems at age 10 years: results from a prospective birth cohort study (German Infant Nutrition Intervention plus). J Allergy Clin Immunol 2010; 125: 404–10.
33 Pedersen MS, Benros ME, Agerbo E et al. Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophr Res 2012; 138: 58–62.

34 Debnath M, Berk M. Th17 pathway-mediated immunopathogenesis of schizophrenia: Mechanisms and implications. Schizophr Bull 2014; 40: 1412–21.

35 Chen M-H, Li C-T, Hsu J-W et al. Atopic diseases and subsequent ischemic stroke among patients with schizophrenia: a nationwide longitudinal study. Psychosom Med 2015; 77: 1031–8.

36 Okusaga O, Hamilton RG, Can A et al. Phadiatop seropositivity in schizophrenia patients and controls: a preliminary study. AIMS public Heal 2014; 1: 43–50.

37 Zaudig M. Heterogenität und Komorbidität der Zwangsstörung Leitthema. Nervenarzt 2011; 82: 290–8.

38 Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet 2009; 374: 491–9.

39 Gunduz S, Usak E, Ozen S, Gorpelioglu C. Obsessive compulsive symptoms and quality of life in mothers of children with atopic dermatitis. Actas Dermosifiliogr 2017; 108: 432–7.

40 Yu SH, Attarian H, Zee P, Silverberg JI. Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis 2016; 27: 50–8.

41 Chamlin SL, Mattson CL, Frieden IJ et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med 2005; 159: 745–50.

42 Chang YS, Chou YT, Lee JH et al. Atopic dermatitis, melatonin, and sleep disturbance. Pediatrics 2014; 134: e397–e405.

43 Fishbein AB, Vitaterna O, Haugh IM et al. Nocturnal eczema: Review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J. Allergy Clin Immunol 2015; 136(5): 1170–7.

44 Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res 1993; 2: 153–9.

45 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6.

46 Dodington SR, Basra MKA, Finlay AY, Salek MS. The dermatitis family impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol 2013; 169: 31–46.

47 Kwak Y, Kim Y. Health-related quality of life and mental health of adults with atopic dermatitis. Arch Psychiatr Nurs 2017; 31: 516–21.

48 Heede NG, Thyssen JP, Thuesen BH et al. Health-related quality of life in adult dermatitis patients stratified by filaggrin genotype. Contact Dermatitis 2017; 76: 167–77.

49 Coutanceau C, Stalder J-F. Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life. Dermatology 2014; 229: 248–55.

50 Klinnert MD, Booster G, Copeland M et al. Role of behavioral health in management of pediatric atopic dermatitis. Ann Allergy Asthma Immunol 2018; 120(1): 42–48.e8.